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Summary Previous studies while demonstrating the presence of blood group isoantigens on normal prostatic
epithelium have failed to identify such antigens on malignant prostatic tissue. Using a series of blood group
specific monoclonal antibodies directed towards the A, B, H and Y antigens we have reinvestigated blood
group isoantigen expression in both benign prostatic hypertrophy and prostatic adenocarcinoma. Results
obtained from areas of benign prostatic hypertrophy are in broad agreement with those published however
though we were unable to detect either A or B blood group isoantigens Type 2H and Y isoantigens were
identified in 10 of the 12 tumours. These findings, while differing from previously reported results, lend
support to the suggested connection between ontogenesis, oncogenesis and blood group isoantigen expression
and also support the proposed link between Type 2 structures and malignant transformation.
The pattern of epithelial A, B and H isoantigen
expression during both foetal development and
adult life has been described by Szulman
(1960,1962,1964). These studies have suggested that
a relationship exists between blood group
isoantigen (BGI) expression and ontogenesis.
Additional support relating the progressive
development of BGI to the degree of cellular
differentiation has come from other studies.
Szulman (1969,1962) observed that while BGIs
were absent from the germinal layer of epithelial
structures such as cervical epithelium, they gained
expression. In a study on cervical derived HeLa
related cellular differentiation to changes in BGI
expression. In a study on cervical derived HeLa
cells (Pann & Kuhns, 1972) a similar relationship
was identified between a BGI negative (H-)
germinative cell layer and a BGI positive (H+)
exfoliated cell population which developed after
several days in culture.
Further evidence linking blood group carbo-
hydrate chain development to both ontogenesis
and oncogenesis has arisen from the examination
of more complex carbohydrate structures con-
ferring either the A or H isoantigens to a cell.
Hakomori and colleagues, by identifying and
detailing the distribution of the blood group
carbohydrate structures (Aa,Ab,Ac,Ad and H1, H2
and H3 antigens) in foetal and adult erythrocytes
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and in gastrointestinal tumours, established the
general concept that: (a) ontogenesis is
accompanied by a step-by-step elongation and
arborization of a complex carbohydrate chain, and
(b) blocking the process of elongation and
arborization occurs during oncogenesis as a result
of a blocked ontogenic programme (Watabane &
Hakomori, 1976; Hakomori et al., 1977).
A relationship between BGI expression and
malignant transformation has now been well
established in a number of epithelial malignancies
(Finan et al., 1983; Thorpe et al., 1983). Several
mechanisms for the change in BGI expression that
occurs have been postulated. It would seem most
likely that the well documented reduction in blood
group structures that occur in the majority of
epithelial tissues following the development of
malignancy results from the progressive loss of the
necessary glycosyl transferases. A reduction in the
level of these enzymes from those seen in normal
tissue has been noted in material derived from
several malignancies (Stellner et al., 1973; Kim &
Isaacs, 1975). Such an interference with the
progressive development of BGIs would be
expected to be associated with an accumulation of
blood group precursor substances, the deletion of A
and B glycosyl transferases being associated with an
accumulation of H substance. It has been suggested
that a Type 2 chain carbohydrate structure is the
most prevalent form of A, B and H antigen present
in malignant tissue (Wherrett & Hakomon, 1973) it
would thus be expected that the Type 2H
isoantigen and its difucosyl substituted counterpart,
the Y antigen would be the dominant blood group
substances in malignant tissue.
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Previous studies on BGI expression in normal,
benign and malignant prostatic tissue have
produced conflicting results. In Szulman's original
studies (1960) on A and B BGIs in adult tissue it
was reported that specific staining was seen at the
luminal tips of single or groups of glandular
epithelial cells in secretor subjects only while in
areas of benign hypertrophy and corposa amylacea
no BGIs were identified. Gupta et al. (1973) using a
mixed cell agglutination reaction and formalin-fixed
paraffin-embedded material described an increase in
BGIs in the majority of cases of benign prostatic
hypetrophy while in primary and metastatic
carcinoma they found no BGIs.
This report describes the results of a study
employing a battery of McAbs to determine the
extent of BGI expression within benign prostatic
hypertrophy and malignancy of the prostate. The
aim being to investigate the possibility that Type
2H and Y isoantigens are expressed on malignant
epithelium while A and B antigens are lost.
Materials and methods
Histological material
We have carried out two studies on the effects of
tissue processing on BGI expression. Using
specimens from colon, stomach, pancreas and
breast we have established that although paraffin
processing reduces the available BGI it never
converted an antigen positive cryostat section to an
antigen deficient paraffin section. In addition we
examined the effects of each stage of the fixing and
paraffin-embedding process on BGI expression by
HT29 cells. (A group A human colon cell line that
expresses A, H and Y antigens in culture.) These
studies demonstrated that a reduction in BGI
expression occurred during tissue processing.
However, although individual cells become 'antigen
deficient' the overall staining of each cell clump
remained positive (unpublished data). For ease of
access to material we therefore used formalin-fixed
paraffin-embedded specimens obtained from the
Pathology Department, Addenbrooke's Hospital,
Cambridge, England for this study. A minimum of
three blocks containing prostatic chippings removed
during transurethral prostatic resection from 12
cases of benign prostatic hypertrophy and 12 cases
of prostatic malignancy were examined. The
distribution of blood groups is shown in the
accompanying tables. In addition 6 specimens of
normal prostatic tissue (2 group A, I group B and
3 group 0) were examined.
Monoclonal antibodies
Six mouse McAbs with known blood group
specificity were used.
Anti-A and Anti-B Supernatant from stable cloned
hybrids secreting mouse anti-A (A15/3D3.92.1) and
anti-B (NB1/19.112.28) McAbs were obtained from
the MRC Laboratory of Molecular Biology,
Cambridge. Both are IgM type immunoglobulins,
the supernatants of each containing - 14pgml- 1 of
immunoglobulin. The specificities of these McAbs
and their use as immunohistochemical reagents
have been described elsewhere (Voak et al., 1982;
Lowe et al., 1983; Finan et al., 1983; Chapman et
al., 1983).
Anti-H Three anti-H McAbs were used in this
study. Two, 101 McAb and 102 McAb, were kindly
provided by Dr Pastan (Laboratory of Molecular
Biology, National Institute of Health, National
Cancer Institute, Bethesda, Maryland 20205, USA).
They are both the product of a hybridoma obtained
by immunizing mice with a human epidermoid
carcinoma cell line A431. McAb 101 was found to
precipitate a receptor for epidermal growth factor
(EGF) and also to bind to several neutral
glycolipids. Binding inhibition assays initially
suggested that this antibody was directed against
human blood group H Type 1 sugar sequence
Fuca(l -2)Galf(l -3)GlcNAc..., a sequence
which presumably also occurs in the EGF receptor
glycoprotein (Fredman et al., 1983; Richert et al.,
1983). Binding assays have recently shown that 101
McAb does in fact bind to both Type 1 and 2 H
structures (Dr Pastan personal communication).
102 McAb is the product of another hybridoma
obtained from the same fusion experiment. Binding
inhibition assays have however shown that this
McAb is directed against human blood group H
Type 2 structure Fuca(1-2)Gal#(1-4)GlcNAc...
(Fredman et al., 1983). Both these McAbs were
provided as samples of ascitic fluid. 101 McAb is an
IgG class antibody, the ascitic fluid containing
500pgml- of immunoglobulin, 102 McAb is IgM
class, the ascitic fluid containing 48pgml-1 of
immunoglobulin. Both McAbs were used at a
dilution of 1: 75 in PBS (Dulbecco's 'A' tabs: Oxoid
Ltd., Basingstoke, UK). An additional comparison
was made with a commercial anti-H mouse McAb
(Dako Corporation, USA). This McAb was used at
the suggested dilution of I in 20.
Anti-Y F-3 McAb was kindly provided by Dr
K.O. Lloyd (Memorial Sloan-Kettering Cancer
Centre, New York, NY 10021) and is the product
of a hybrid clone resulting from a fusion using
spleen cells from a mouse immunised with a human
lung cancer cell line (SK-LC-3). Binding and
inhibition studies with a series of glycolipids with H
and Lewis specificities and both Type 1 and Type 2
backbone structure have established that the onlyABH AND Y ISOANTIGENS AND THE PROSTATE 309
antigen to which binding occurs is the difucosyl
Type 2 structure, the Y antigen (Lloyd et al., 1983).
In this study a sample of ascitic fluid obtained from
Dr Lloyd was diluted 1: 150 in PBS.
Optimal dilutions were established for all McAbs
and were defined as the concentration that
produced the maximum staining of endothelial and
red cell elements with acceptable (or absent) non-
specific background staining. All McAbs contained
0.1% azide and were stored at -20°C. Those
samples in current use were kept at 4°C.
Immunoperoxidase technique
The use of McAbs in an indirect immuno-
peroxidase technique has been described elsewhere
(Finan et al., 1982a,b). Briefly 5p,m sections were
cut from each paraffin block and mounted on
microscope slides previously treated with a chrome
alum solution. Sections were then dewaxed in xylene
and rehydrated through alcohols to water.
Endogenous peroxidase activity was blocked by
incubating the slides with hydrogen peroxide and
non-specific binding blocked with rabbit serum.
Sections were then incubated for 30min with 1001il
of either a blood group specific McAb or a control
solution. After further washes in PBS the sections
were then incubated with 10041 of a 1:100 dilution,
in PBS, of rabbit anti-mouse peroxidase conjugate
(Miles-Yeda Ltd., Rehovot, Israel). After further
washes in PBS sections were flooded with a freshly
prepared solution containing 10mg diamino-
benzidine, 40pl 100vol hydrogen peroxide and
20ml PBS for 5min. Slides were then counter-
stained with Mayer's haemalum, blued, dehydrated,
cleared and mounted in DPX mountant. Sections
were viewed under an Olympus CH microscope and
photographed onto KB14 film (ASA 20).
Controls
Positive controls were provided by sections of
gastric mucosa from a group AB patient. Vascular
endothelium and erythrocytes present in tissue
Table I Staining observed in the 12 specimens of benign
prostatic hypertrophy
Monoclonal antibodies
Bloodgroup A15/3D3 NBJ/19 Dako H 101 102 F-3
Group A4 4 0 4 4 4 4
Group B 2 0 2 2 2 2 2
Group 06 0 0 6 6 6 6
Numbers indicate those specimens showing staining
with each McAb.
sections acted as internal positive and negative
controls for each specimen. Medium controls
included incubation with inappropriate blood group
McAbs, antibody free medium (Dulbecco's Modified
Eagles essential medium with 10% foetal calf
serum), PBS, non-immune mouse serum diluted
1:150 in PBS and absorbed McAbs produced by
incubating the appropriate McAb overnight with
isologous erythrocytes at 4°C.
Results
In areas of normal prostatic tissue little difference in
staining intensity was noted when either the
appropriate anti-A or anti-B McAbs were used or
when any of the three anti-H or the anti-Y McAbs
were used. Generally areas of benign prostatic
hypertrophy showed less staining than normal
structures. A considerable variation in staining
intensity between apparently histologically similar
areas within the same specimen was a common
finding. A, B and H isoantigens were all found
within the appropriate specimens (see Table I).
Figure 1 shows the typical pattern of antigen
expression seen in specimens showing benign
prostatic hypertrophy.
Within malignant prostatic epithelium a different
pattern of staining was seen. We failed to identify
either A (0 from 5 group A specimens) or B (0 from
1 group B specimen) BGIs while the H and Y
isoantigens were identified in 10 of 12 specimens
(see Table II). Figure 2 shows the pattern of
staining seen in a prostatic tumour from a group A
specimen stained with 102 McAb. Of the anti-H
McAbs studied 102 McAb detected a Type 2H
structure in all 10 antigen positive tumours (the 5
group A and the group B tumours all displaying a
Type 2H antigen). The remaining anti-H McAbs
produced staining in only 3 of the 12 tumours
(101 McAb) and 1 of the 12 tumours (commercial
anti-H) respectively. Areas of normal prostatic
epithelium present in the same 12 specimens stained
with all three anti-H McAbs. Staining with F-3
(anti-Y) McAb almost exactly paralleled that seen
with McAb 102, the Y antigen being detected in 10
of 12 tumours. However, in 2 cases staining could
only be detected with either 102 or F-3 McAb.
Staining was noted in the positive control gastric
mucosa slides with all six McAbs. Similarly
vascular structures and erythrocytes stained with
the appropriate McAbs in all cases. At the dilutions
used however this was much more marked with
A15/3D3.92.1 and NB1/19.112.28 than with the
anti-H and Y McAbs. None of the negative control
slides showed staining of erythrocytes, endothelium
or epithelial structures, in addition no inappropriate310 P. VOWDEN et al.
BGIs were identified.
urothelium was found to
BGI in all cases.
Figure 1 Section from a group A specimen showing
benign prostatic hypertrophy. Weak staining of
isolated epithelial cells and staining of blood vessels
with A15/3D3.92.1 McAb. x 200. Counterstained with
haemalum.
Figure 2 Section from a group A moderately well
differentiated prostatic adenocarcinoma stained with
102 McAb. Note the widespread but patchy intensity
of staining seen in this tumour which failed to stain for




In this study on BGI expression in prostatic
epithelium we have found a pattern of BGI
expression in normal tissue that closely agrees with
that described by Szulman (1960,1962,1964) but
which differs somewhat from those observations
made by Gupta et al. (1973) who found an increase
in BGIs in benign prostatic hypertrophy. In the
present study no such increase was found.
In the areas of malignant transformation marked
differences exist between our observations and
those reported previously. Gupta et al. (1973),
using a mixed cell agglutination reaction, A and B
antisera and Ulex europus extract (anti-H) failed to
identify BGIs in 15 cases of primary and secondary
adenocarcinomas of the prostate. While we failed to
demonstrate the presence of either A or B
isoantigens, both H and Y isoantigens were readily
demonstrated in 10 of 12 (84%) of the primary
prostatic adenocarcinomas examined. Maximal
staining of malignant tissue was observed with 102
and F-3 McAbs both of which have been
demonstrated to bind specifically to Type 2
structures. These findings may therefore give some
support to suggestions made by Wherrett and
Hakomori (1973) that Type 2 structures
predominante in malignant epithelium. It would
seem more likely however that both Type 1 and 2
structures are present in malignant tissue for both
Hansson et al. (1983) and Picard and Feizi (1984)
have demonstrated that antigens with a Type 1
Table II Distribution ofstaining observed in the 12 prostatic tumours examined
Monoclonal antibodies
Blood
Histology group A15/3D3 NBI/19 Dako H 101 102 F-3
Well Dif. A - - + - + + + +
Well Dif. B - - - - + + +
Well Dif. 0 - - - - - +
Well Dif. 0 - -
Mod. W. Dif. 0 - - +- +- ++ ++
Mod. W. Dif. 0 - - - - ++ ++
Mod. W. Dif. 0 - - + + ++ +++
Mod. Dif. A - - + +- +/+ + +/+ +
Mod. Dif. A - - - - +/- -
Mod. Dif. A - - +- -/++ ++ +++
Poorly Dif. A - - - - + +
Poorly Dif. 0 - - - - -/+ + -/+ +
Staining intensity has been graded between negative (-) and + + +, where
considerable variation exists within a tumour the two extremes have been shown (/),
+ - indicates that only isolated cells showed BGI expression.ABH AND Y ISOANTIGENS AND THE PROSTATE 311
structure are present in gastrointestinal tract
malignancies.
Differences in the relative affinity of Ulex
europus extracts for Type 1 and Type 2 structures
have been demonstrated but as preferential binding
is to a Type 2H antigen the difference between our
results and those reported earlier cannot be
explained on these grounds. A number of previous
studies have however indicated that Ulex europus
extract produces inconsistent results when used to
localise the H isoantigen (Cooper & Haesler, 1978;
Ramsey, 1980). Our use of anti-H McAbs probably
explains the increase in H isoantigen detection in
the present series.
The staining of malignant prostatic tissue with
F-3 McAb, which recognises a difucosyl Type 2
structure, the Y antigen, not only offers support for
the presence of a Type 2H structure within the
adenocarcinomas examined but also may be taken
as indirect evidence for a reduction in the levels of
A and B glycosyl transferases. In studies of specific
glycosyl transferases in malignant tissue both
Stellner et al. (1973) and Kim & Isaacs (1975) have
established that the enzymes necessary to confer
either A or B characterisation to the stem structure,
the H antigen, are often reduced in malignant cells.
The present study would certainly offer support for
these findings.
To conclude, in contrast to previous reports
results we have demonstrated the presence of BGI
in prostatic malignancies, It would appear that both
A and B structures are lost or greatly reduced in
the malignant process but that there is a continued
expression of both the H and Y antigens in the
great majority of these tumours. The staining
observed indicates that a Type 2H structure is
maintained and may well predominate in malignant
tissue within the prostate. Further studies are being
undertaken to determine whether this pattern
persists in other malignancies.
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